Literature DB >> 18448619

Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.

R L Tallmadge1, M A Brindley, J Salmans, R H Mealey, W Maury, S Carpenter.   

Abstract

We developed a replication-defective reporter virus pseudotyped with the envelope glycoprotein of equine infectious anemia virus (EIAV). The in vitro host range and neutralization phenotype of EIAV Env-pseudotyped virus were similar to those of replication-competent virus. An EIAV Env pseudovirus will improve antigenic characterization of viral variants and evaluation of lentivirus vaccines.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18448619      PMCID： PMC2446648          DOI： 10.1128/CVI.00088-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  22 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.

Authors:  M Belshan; P Baccam; J L Oaks; B A Sponseller; S C Murphy; J Cornette; S Carpenter
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

3.  Endotoxin treatment of equine infectious anaemia virus-infected horse macrophage cultures decreases production of infectious virus.

Authors:  T A Smith; E Davis; S Carpenter
Journal:  J Gen Virol       Date:  1998-04       Impact factor: 3.891

4.  Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.

Authors:  S A Hammond; S J Cook; D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Vera Goossens; Sofie Priem; Hugo Walter; Erik Depla; Ann Union; Kristina N Faulk; Jens Bukh; Suzanne U Emerson; Robert H Purcell
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

7.  Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors.

Authors:  T P Cunningham; R C Montelaro; K E Rushlow
Journal:  Gene       Date:  1993-02-14       Impact factor: 3.688

8.  Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.

Authors:  L E Perryman; K I O'Rourke; T C McGuire
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 9.  The immunopathogenesis of equine infectious anemia virus.

Authors:  D C Sellon; F J Fuller; T C McGuire
Journal:  Virus Res       Date:  1994-05       Impact factor: 3.303

10.  Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.

Authors:  Yuchun Nie; Guangwen Wang; Xuanling Shi; Hong Zhang; Yan Qiu; Zhongping He; Wei Wang; Gewei Lian; Xiaolei Yin; Liying Du; Lili Ren; Jianwei Wang; Xiong He; Taisheng Li; Hongkui Deng; Mingxiao Ding
Journal:  J Infect Dis       Date:  2004-08-02       Impact factor: 5.226
View more
  6 in total

1.  Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.

Authors:  Wuwei Wu; Derek C Blythe; Hyelee Loyd; Robert H Mealey; Rebecca L Tallmadge; Karin S Dorman; Susan Carpenter
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.

Authors:  Sandra D Taylor; Steven R Leib; Wuwei Wu; Robert Nelson; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

Authors:  Ajit Chande; Emilia Cristiana Cuccurullo; Annachiara Rosa; Serena Ziglio; Susan Carpenter; Massimo Pizzato
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-01       Impact factor: 11.205

4.  An equine infectious anemia virus variant superinfects cells through novel receptor interactions.

Authors:  Melinda A Brindley; Baoshan Zhang; Ronald C Montelaro; Wendy Maury
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

5.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

6.  Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.

Authors:  Kathleen A Ross; Hyelee Loyd; Wuwei Wu; Lucas Huntimer; Shaheen Ahmed; Anthony Sambol; Scott Broderick; Zachary Flickinger; Krishna Rajan; Tatiana Bronich; Surya Mallapragada; Michael J Wannemuehler; Susan Carpenter; Balaji Narasimhan
Journal:  Int J Nanomedicine       Date:  2014-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.